Executive Summary
Post-TAVI antithrombotic strategy just got messier: ACASA-TAVI (JAMA) showed 12 months of DOAC monotherapy nearly halved subclinical leaflet thrombosis versus aspirin (16.2% vs 28.6%, RR 0.55) without an unacceptable bleeding penalty, while NOTION-4 (JACC) found that 3 months of DOAC therapy produced no durable HALT reduction at 1 year and increased the composite of death, stroke, and major bleeding (8.2% vs 2.3%, P=0.008). Both ESC Congress hot lines land on the same day Medtronic committed up to $80M (with a $210M buyout option) to Pi-Cardia's ShortCut leaflet-splitting device, signaling that industry is betting durability and reintervention — not initial deployment — is the next battleground. A meta-analysis of 2,327 patients finds the Myval platform hemodynamically competitive with SAPIEN and Evolut at 1 year, and a Japanese nationwide cohort of 1,649 dialysis patients reports lower in-hospital mortality with TAVI than SAVR — findings that complicate the guideline calculus for younger and higher-risk populations alike.
- ACASA-TAVI: 12-month DOAC monotherapy cut HALT by 45% and grade 3-4 HALT from 9.0% to 0.6% versus aspirin, with numerically fewer deaths (1.1% vs 5.6%) (JAMA, via TCTMD).
- NOTION-4: short-course DOAC produced early HALT reduction that vanished by 12 months and tripled the composite safety endpoint versus antiplatelet monotherapy (JACC, via TCTMD).
- Medtronic's Pi-Cardia investment positions ShortCut leaflet modification as a portfolio hedge against rising valve-in-valve coronary obstruction risk (Cardiovascular Business).
- Japanese registry of 1,649 dialysis patients: TAVI in-hospital mortality 3.0% vs SAVR 5.9% (adjusted OR 0.44), attenuated to OR 0.75 when restricted to dual-capability centers (Cardiovasc Interv Ther).
- Myval meta-analysis (5 studies, N=2,327): comparable 1-year mortality, stroke, and pacemaker rates versus SAPIEN/Evolut, with lower mean gradients (-1.28 mmHg) versus SAPIEN (Cardiology in Review).
Watch for the ACASA-TAVI 5- and 10-year follow-up: without conversion of the HALT signal into a hard durability endpoint, guidelines will hold to aspirin monotherapy on NOTION-4's safety numbers.
Aortic Valve (TAVR/TAVI)
Two same-day randomized trials from ESC Congress reach different conclusions on post-TAVI DOACs, and the discrepancy is duration, not direction. ACASA-TAVI (N=360, JAMA) randomized patients aged 65-80 to 12 months of apixaban, edoxaban, or rivaroxaban versus aspirin 75 mg. HALT dropped from 28.6% to 16.2% (RR 0.55) and grade 3-4 HALT from 9.0% to 0.6%. The safety composite met noninferiority — but on very few events (2 deaths in the DOAC arm, 10 in aspirin), in a single-country, three-center design. NOTION-4 (N=352, JACC) tested 3 months of DOAC followed by aspirin: early HALT reduction at 3 months (12.1% vs 31.8%) evaporated by 12 months (28.3% vs 32.2%), while the death/stroke/major bleeding composite ran 8.2% vs 2.3% (P=0.008). Discussant Windecker's read: single antiplatelet remains the default. That aligns with both ACC/AHA 2020 and ESC 2025, neither of which endorses routine DOACs post-TAVI absent another indication. The unresolved question is whether ACASA-TAVI's HALT signal translates to structural valve deterioration at 5-10 years — which matters more as TAVI penetrates the ESC's newly-lowered age-70 threshold for tricuspid AV patients.
A Japanese nationwide cohort of 1,649 hemodialysis patients found TAVI in-hospital mortality 3.0% versus SAVR 5.9% (adjusted OR 0.44). The structural limitations are significant: retrospective, administrative database, no long-term durability data, and the effect attenuated to OR 0.75 (non-significant) at dual-capability centers — where the truest comparison lives. Dialysis patients were excluded from PARTNER, Evolut Low Risk, and DEDICATE, so neither ACC/AHA 2020 nor ESC 2025 provides a dialysis-specific pathway. The ESC's <4% STS-PROM + EuroSCORE II threshold for SAVR preference is functionally unreachable for most dialysis patients, effectively pushing them toward TAVI by default — not by evidence.
A meta-analysis of Myval versus contemporary THVs (5 studies, N=2,327) shows comparable 1-year mortality and stroke and better hemodynamics than SAPIEN (mean gradient -1.28 mmHg, EOA +0.15 cm²) — consistent with the recent LANDMARK trial, but durability data past 1 year remain absent. ESC 2025 and ACC/AHA 2020 both emphasize lifetime management planning; a 1-year hemodynamic advantage carries no guideline weight without longer follow-up. A single-center retrospective (N=1,101) reports lower periprocedural ischemic stroke with cerebral embolic protection (1.4% vs 4.1%) — directionally consistent with existing meta-analyses but insufficient to overturn PROTECTED TAVR's negative primary endpoint. Acurate Neo 2 outperformed its predecessor on device success (94.7% vs 86.3%) and paravalvular leak, though midframe underexpansion — occurring in 13.3% — degraded 1-year outcomes regardless of generation.
Mitral Valve (MitraClip, PASCAL, TMVR)
A case series of three high-risk valve-in-valve TMVR procedures describes a modified transseptal BATMAN technique (balloon-assisted anterior leaflet translocation) to prevent LVOT obstruction — a mechanistic solution to what remains the dominant failure mode in TMVR. Three patients, single center: this is anecdotal, not practice-changing. The signal matters because it mirrors the Pi-Cardia thesis on the aortic side — leaflet modification as prerequisite to transcatheter therapy. ESC 2025 rates TMVI as Class IIb for degenerative MS with MAC at experienced centers, acknowledging the high-risk nature of all intervention in this anatomy; ACC/AHA 2020 does not endorse TMVR outside investigational contexts. Surgery remains the reference standard for operable patients with mitral annular calcification.
A retrospective analysis of 614 low-flow AS patients post-TAVR found that the classical low-flow low-gradient phenotype had the highest rate of MR worsening at 30 days and the lowest event-free survival — a reminder that concomitant MR management after TAVR remains unresolved. ESC 2025 upgraded TEER for ventricular secondary MR to Class I (LOE A) based on COAPT 5-year follow-up and RESHAPE-HF2, applying to patients with LVEF 20-50%, LVESD ≤70mm, and SPAP ≤70mmHg. ACC/AHA 2020 holds this at Class IIa. That gap is clinically meaningful for post-TAVR patients with persistent ventricular SMR who meet COAPT criteria.
Tricuspid Valve (TriClip, TTVR)
No dedicated tricuspid trial data emerged from this ESC meeting cycle — notable at a congress where TR has been the dominant growth story. The STS/ACC TVT registry EVOQUE experience — 98.4% procedural success, 3.1% 30-day mortality, 15.9% new pacemakers in real-world use, with pacemaker and bleeding rates numerically lower than TRISCEND II — remains the benchmark for transcatheter TV replacement. That real-world signal supports the ESC 2025 Class IIa (LOE A) recommendation for transcatheter TR therapy in high-risk symptomatic severe TR without severe RV dysfunction or pre-capillary pulmonary hypertension. ACC/AHA 2020 does not address transcatheter TR therapy, having predated the pivotal trials. On the surgical side, ESC 2025 upgraded TV surgery for symptomatic severe primary TR to Class I — up from ACC/AHA's IIa — and both guidelines converge on concomitant TV repair during left-sided surgery when tricuspid annular diameter reaches ≥40mm or >21mm/m². Today's silence on TR at ESC underscores the field's unresolved central question: repair versus replacement when RV function is borderline.
Surgical vs. Transcatheter Comparisons
The Japanese hemodialysis cohort is the day's most direct SAVR-versus-TAVI comparison and it favors TAVI on in-hospital endpoints (mortality OR 0.44, length of stay 14 vs 29 days). Two structural caveats define its limits. First, this is a population systematically excluded from PARTNER, Evolut Low Risk, and DEDICATE — the RCTs both guidelines rest on. Second, the effect attenuated to OR 0.75 (non-significant) at dual-capability centers, where the truest apples-to-apples comparison lives. Neither ACC/AHA 2020 nor ESC 2025 provides a dialysis-specific pathway; the ESC's <4% STS-PROM + EuroSCORE II threshold for SAVR preference is functionally unreachable for most dialysis patients, effectively pushing them toward TAVI by default rather than by evidence.
The imaging review on intraprocedural echo during TAVI makes a related point: as TAVI moves into anatomically complex populations — small annulus, BAV, dialysis-related calcification — imaging burden and complication rates rise, arguing against the minimalist-TAVI narrative for expansion populations. ESC 2025 rates TAVI for BAV at increased surgical risk with suitable anatomy as Class IIb, unchanged from ACC/AHA 2020, reflecting the absence of randomized data in this anatomy.
Device & Technology
Medtronic's $80M investment in Pi-Cardia with a $210M buyout option is the day's most consequential technology signal. ShortCut splits native or bioprosthetic leaflets before valve deployment to prevent coronary obstruction — a complication the ESC 2025 lifetime-management framework flags as one of the primary barriers to valve-in-valve TAVR feasibility, alongside sinus sequestration and patient-prosthesis mismatch. Medtronic becomes exclusive global distributor in 2027. Read this alongside Medtronic's January stake in Anteris and the 2024 FDA approval of ShortCut: the majors are building the complex-anatomy toolkit ahead of the redo-TAVR wave, where THV explantation carries 12-17% reported mortality.
A retrospective study of AI-based versus semi-automated CT analysis in 247 TAVI patients found excellent agreement on annular dimensions but noted AI-derived measurements would have changed prosthesis size in 21% of cases versus 14% for semi-automated — expert integration still matters and the clinical consequence of those discrepant sizing decisions is uncharacterized. A prospective 633-patient comparison of hybrid (Perclose + Angio-Seal) versus dual Perclose closure found no difference in vascular complications (4.8% vs 5.0%); antithrombotic status, not device choice, drove events.
Regulatory & Policy
No new FDA or CE mark actions today. The Medtronic-Pi-Cardia deal structure — investment now, buyout on milestones, exclusive distribution 2027 — is the emerging playbook for how large-cap medtech consolidates the complex-TAVR ecosystem without triggering antitrust review of an outright acquisition.
Industry & Market
The Pi-Cardia deal reframes Medtronic's structural heart narrative from Evolut-versus-SAPIEN market share to lifetime valve management — a strategically coherent response to ESC 2025's emphasis on planning for reintervention at the index procedure. Edwards drove today's news cycle with a consumer-facing "Stay Young at Heart" awareness campaign rather than data. The asymmetry — Medtronic buying capability, Edwards buying awareness — reflects Edwards' installed-base advantage and Medtronic's need to differentiate on complex anatomy. Boston Scientific's 6-month stock performance (down 37%) continues to reflect Acurate IDE and market-share pressures that today's Acurate Neo 2 data only partially address.
Financial Analysis
The ACASA-TAVI HALT reduction signal is neutral-to-modestly-positive for Edwards and Medtronic on the durability narrative — the 5-year follow-up plan is what to watch. The Pi-Cardia investment consumes modest capital ($80M initial) against a $210M milestone-gated buyout, small on Medtronic's balance sheet but strategically outsized: it locks in leaflet-modification capability ahead of the redo-TAVR wave. Edwards options activity has been notably bullish into Q3, per Yahoo Finance, ahead of the October 29 earnings print. The clinical read-through: if long-term DOAC becomes standard, it disproportionately benefits patients with mechanically imperfect deployments — arguing for platforms with the lowest baseline HALT rates (Sapien 3 Ultra, Evolut FX, Acurate Neo 2) and against older-generation valves.
Valve Industry Stocks
Edwards Lifesciences (EW)
EW closed at $90.74 (flat on the day), with a 6-month gain of 4.08% against a 52-week range of $72.30-$96.29. Market cap $52.3B, trailing P/E 54.01 (forward 26.87), beta 0.85. Analyst consensus target $100.96 (26 analysts, buy). Next earnings October 29 with EPS estimate $0.74 on revenue of $1.68B. Bullish options positioning and steady institutional buying reflect confidence in Edwards' TAVI and TR franchise ahead of the print, though the ACASA-TAVI HALT signal is a mild tailwind for platforms with better sealing profiles.
Medtronic (MDT)
MDT closed at $92.04, up 1.53% on the Pi-Cardia news, though 6-month performance remains -4.56%. Market cap $117.8B, trailing P/E 24.68 (forward 14.38), beta 0.57. Analyst consensus $98.84 (25 analysts, buy). Earnings today (September 1) with EPS estimate $1.39 on revenue of $9.54B. The Pi-Cardia investment plus January's Anteris stake position Medtronic for the complex-TAVR expansion cycle; execution on Evolut FX volume growth remains the swing factor.
Abbott (ABT)
ABT closed at $108.93 (-1.30%), 6-month change -3.26%. Market cap $188.5B, trailing P/E 35.25 (forward 17.96), beta 0.58. Analyst consensus $120.20 (25 analysts, buy). Next earnings October 14 with EPS estimate $1.42 on revenue of $12.99B. MitraClip volumes benefit from the ESC 2025 Class I upgrade for ventricular SMR, but TriClip's TR franchise faces incremental competition from Edwards EVOQUE.
Boston Scientific (BSX)
BSX closed at $48.08 (-0.46%), with a 6-month decline of 36.92% against a 52-week range of $42.20-$109.50. Market cap $69.7B, trailing P/E 19.47 (forward 14.00). Analyst consensus $62.69 (29 analysts, buy) implies 30% upside. Today's Acurate Neo 2 data showing improved device success and PVL profile is supportive but doesn't undo the market's Acurate IDE overhang. Next earnings October 28.
Anteris Technologies (AVR.AX)
AVR.AX closed at $11.75 AUD (-1.34%), 6-month change +33.52%. Market cap $1.1B AUD. Continued strength reflects Medtronic strategic backing from January and the DurAVR pivotal trial trajectory.
The industry is pricing in a bifurcation — winners on complex-anatomy platforms and leaflet modification, losers on undifferentiated first-generation devices. The ACASA-TAVI/NOTION-4 discordance keeps antithrombotic ambiguity alive, which favors platforms with the lowest baseline HALT rates.
Clinical Trial Updates
Aortic
- NCT06833762 — Clinical and CPET Parameters That Predict Improvement in Functional Capacity After TAVI. Status: Recruiting. Enrollment: 161. Sponsor: Hospital Clinic of Barcelona. Functional-capacity endpoints matter more as TAVI expands into ESC's newly designated ≥70 tricuspid AV population.
- NCT07798713 — Quality of Life After Transcatheter Aortic Valve Implantation. Status: Active, not recruiting. Enrollment: 200. Sponsor: Aalborg University Hospital.
EARLY TAVR, PARTNER 3 long-term, Evolut Low Risk 10-year, and DEDICATE follow-up cohorts remain the reference set for the next ACC/AHA guideline revision. TRILUMINATE Pivotal and TRISCEND II continue to define the tricuspid transcatheter benchmark; COAPT 5-year and RESHAPE-HF2 anchor the mitral TEER Class I in ESC 2025.
Social & Conference Highlights
ESC Congress delivered its structural heart headline with the ACASA-TAVI/NOTION-4 hot line and simultaneous JAMA/JACC publications. The TCTMD readout of Windecker's discussion — "single antiplatelet therapy remains the default strategy" — will define practice through 2027 unless the ACASA-TAVI 5-year data change the durability equation. North Mississippi Medical Center's 1,000th TAVR case underscores how deeply the procedure has penetrated community practice — a volume story that keeps procedural safety, not incremental efficacy, at the center of adoption.
Watch for the ACASA-TAVI 5-year interim analysis, which will determine whether the HALT signal converts to a durability endpoint that changes ESC and ACC/AHA antithrombotic guidance. Between now and then, expect Medtronic to accelerate integration of leaflet-modification capabilities and Edwards to defend on data volume and installed base.